Patni, Nivedita
Garg, Abhimanyu
Article History
Accepted: 3 June 2022
First Online: 11 July 2022
Declarations
:
: N.P. have no financial or non-financial interests that are directly or indirectly related to the work submitted for publication. A.G. consults for Amryt Pharma PLC and Regeneron and has received grant support from Amryt Pharma PLC, Regeneron, Quintiles, Akcea Pharmaceuticals, and Intercept Pharmaceuticals. A.G. is coholder of a patent for “use of leptin for treating human lipoatrophy and a method of determining predisposition to said treatment” but receives no financial compensation.